Sign/Symptoms |
Our Records are Incomplete for Signs and Symptoms |
Drugs |
Our Records are Incomplete for Drugs |
Treatments |
Attributes |
commonality is rare |
Further Tests |
Our Records are Incomplete for Further Tests |
Recommendation: no recommendation (there is insufficient evidence to show that Biofeedback helps treat insomnia)
Grade of Evidence: very low quality of evidence
Recommendation: strongly in favor (research has shown that meditation can help to treat insomnia)
Grade of Evidence: moderate quality of evidence
* www.gradeworkinggroup.org
Fatal familial insomnia (FFI) is a very rare autosomal dominant inherited prion disease of the brain. The dominant gene responsible has been found in just 28 families worldwide; if only one parent has the gene, the offspring have a 50% chance of inheriting it and developing the disease. The disease's genesis and the patient's progression into complete sleeplessness is untreatable, and ultimately fatal.
PrPsc has autocatalytic properties that cause normally soluble PrP to be converted into the PrPsc form upon interaction.
This conversion into insoluble protein causes plaques containing aggregates of PrPsc to develop in the thalamus, a region of the brain responsible for regulation of sleep. This first results in insomnia, and then progresses to more serious problems over time.
The age of onset is variable, ranging from 30 to 60, with an average of 50. However the disease tends to prominently occur in later years, primarily following childbirth. Death usually occurs between 7 to 36 months from onset. The presentation of the disease varies considerably from person to person, even among patients from within the same family.
The disease has four stages, taking 7 to 18 months to run its course:
There is no cure or treatment for FFI; hope rests on the so far unsuccessful gene therapy. Sleeping pills have no effect.
While it is not currently possible to reverse the underlying illness, there is some evidence that treatment modalities that focus upon the symptoms can improve quality of life.